 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12345678910111213...1718» |
- | Pemazyre (pemigatinib) / Incyte
Trial completion date, Trial primary completion date: Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 8, 2024
P1, N=32, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial completion date: Aug 2024 --> Feb 2026 | Trial primary completion date: Feb 2024 --> Aug 2025
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment open: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 8, 2024
P2, N=80, Recruiting, Sponsor: Children's Oncology Group
Trial completion date: Aug 2024 --> Feb 2026 | Trial primary completion date: Feb 2024 --> Aug 2025 Active, not recruiting --> Recruiting
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial completion date: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 5, 2024
P3, N=1895, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | Enrollment change: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - Apr 4, 2024
P2, N=80, Recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Recruiting N=55 --> 80
- | revumenib (SNDX-5613) / Syndax Pharma
Enrollment open, Combination therapy: A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia (clinicaltrials.gov) - Mar 19, 2024
P2, N=78, Recruiting, Sponsor: Children's Oncology Group
N=55 --> 80 Active, not recruiting --> Recruiting
- | Trial completion date, Trial primary completion date: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - Mar 17, 2024
P2, N=55, Recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Recruiting Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Dec 2025
- | revumenib (SNDX-5613) / Syndax Pharma
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene (clinicaltrials.gov) - Mar 12, 2024
P1, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Dec 2025 Not yet recruiting --> Recruiting | Trial completion date: Feb 2024 --> Dec 2027 | Initiation date: Feb 2024 --> Nov 2024 | Trial primary completion date: Feb 2024 --> Dec 2027
- | Xospata (gilteritinib) / Astellas, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Enrollment closed: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov) - Mar 12, 2024
P3, N=1400, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting | Trial completion date: Feb 2024 --> Dec 2027 | Initiation date: Feb 2024 --> Nov 2024 | Trial primary completion date: Feb 2024 --> Dec 2027 Recruiting --> Active, not recruiting
- | Venclexta (venetoclax) / Roche, AbbVie
Trial completion date, Trial primary completion date: Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) (clinicaltrials.gov) - Mar 2, 2024
P2, N=153, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date: AALL1732: Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (clinicaltrials.gov) - Mar 2, 2024
P3, N=4997, Recruiting, Sponsor: Children's Oncology Group
Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025 Trial completion date: Jun 2029 --> Mar 2030 | Trial primary completion date: Jun 2029 --> Mar 2030
- || Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: NCI-2018-01078: Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 2, 2024
P2, N=90, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jun 2029 --> Mar 2030 | Trial primary completion date: Jun 2029 --> Mar 2030 Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025
- | Vanflyta (quizartinib) / Daiichi Sankyo
Enrollment change: NCI-2018-01813: Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 28, 2024
P1/2, N=73, Completed, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025 N=200 --> 73
- | Rydapt (midostaurin) / Novartis, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial primary completion date, Combination therapy: NCI-2019-01726: Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 15, 2024
P1, N=18, Recruiting, Sponsor: Uma Borate
N=200 --> 73 Trial primary completion date: Jan 2024 --> Jan 2025
- | revumenib (SNDX-5613) / Syndax Pharma
Enrollment closed, Combination therapy: A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia (clinicaltrials.gov) - Feb 15, 2024
P2, N=78, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Jan 2024 --> Jan 2025 Recruiting --> Active, not recruiting
- | dasatinib / Generic mfg.
Trial completion date: Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 15, 2024
P2, N=97, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial completion date: Jan 2024 --> Jan 2025
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov) - Feb 15, 2024
P2, N=53, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Center
Trial completion date: Jan 2024 --> Jan 2025 N=80 --> 53
- | Asparec (PEGylated recombinant Erwinia chrysantemi-derived L-asparaginase) / Jazz
Enrollment closed: Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia (clinicaltrials.gov) - Feb 13, 2024
P1, N=19, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=80 --> 53 Recruiting --> Active, not recruiting
- | imetelstat (GRN163L) / Geron
New P1 trial, Combination therapy: A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (clinicaltrials.gov) - Feb 7, 2024
P1, N=36, Not yet recruiting, Sponsor: Children's Oncology Group
- | Arzerra (ofatumumab) / Novartis, Genmab
Trial completion, Combination therapy: NCI-2011-03562: Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Feb 6, 2024
P2, N=37, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | uproleselan sodium (APL-106) / GlycoMimetics
Enrollment closed: Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 2, 2024
P1/2, N=37, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed, Trial completion date, Trial primary completion date: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov) - Jan 31, 2024
P2, N=80, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Jun 2033 --> Jan 2030 | Trial primary completion date: Jan 2028 --> Jan 2025
- | pevonedistat (MLN4924) / Takeda
Trial completion, Trial completion date, Combination therapy: ADVL1712: Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 31, 2024
P1, N=12, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial completion date: Jun 2033 --> Jan 2030 | Trial primary completion date: Jan 2028 --> Jan 2025 Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Dec 2023
- | Starasid (cytarabine ocfosfate) / Nippon Kayaku
Enrollment change, Trial completion date: FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 24, 2024
P2, N=87, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Dec 2023 N=57 --> 87 | Trial completion date: Dec 2023 --> Jan 2025
- | Qinprezo (vosaroxin) / Denovo
Trial completion date, Combination therapy, Tumor mutational burden: VITAL: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 18, 2024
P2, N=42, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
N=57 --> 87 | Trial completion date: Dec 2023 --> Jan 2025 Trial completion date: Jan 2024 --> Apr 2024
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Starasid (cytarabine ocfosfate) / Nippon Kayaku
Trial completion date, Trial primary completion date: CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - Jan 11, 2024
P1, N=120, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Trial completion date: Jan 2024 --> Apr 2024 Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2025
- | navtemadlin (KRT-232) / Kartos Therap
Phase classification, Combination therapy: Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 11, 2024
P1, N=24, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2025 Phase classification: P1b --> P1
- | pevonedistat (MLN4924) / Takeda
Phase classification, Combination therapy: Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 9, 2024
P1/2, N=53, Active, not recruiting, Sponsor: University of Southern California
Phase classification: P1b --> P1 Phase classification: P1b --> P1/2
- | peposertib (M3814) / EMD Serono
Trial completion date, Trial primary completion date, Combination therapy: Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 21, 2023
P1, N=48, Recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P1b --> P1/2 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Venclexta (venetoclax) / Roche, AbbVie, Inqovi (decitabine/cedazuridine) / Otsuka
Enrollment closed, Combination therapy, Tumor mutational burden: NCI-2021-02246: Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients (clinicaltrials.gov) - Dec 21, 2023
P1/2, N=55, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Recruiting --> Active, not recruiting
- | revumenib (SNDX-5613) / Syndax Pharma
Phase classification, Combination therapy: Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene (clinicaltrials.gov) - Dec 15, 2023
P1, N=28, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Phase classification: P1b --> P1
- || pivekimab sunirine (IMGN632) / Jazz
Enrollment open: Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms (clinicaltrials.gov) - Dec 14, 2023
P1, N=30, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Phase classification: P1b --> P1 Not yet recruiting --> Recruiting
- | flotetuzumab (MGD006) / MacroGenics
Enrollment change, Trial completion date: PEPN1812: Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 11, 2023
P1, N=16, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting N=47 --> 16 | Trial completion date: Oct 2023 --> Sep 2024
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 7, 2023
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=47 --> 16 | Trial completion date: Oct 2023 --> Sep 2024 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2023
- | revumenib (SNDX-5613) / Syndax Pharma
Enrollment open, Combination therapy: A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia (clinicaltrials.gov) - Dec 5, 2023
P2, N=78, Recruiting, Sponsor: Children's Oncology Group
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2023 Not yet recruiting --> Recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 30, 2023
P3, N=6720, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial completion date: Mar 2030 --> Jun 2029 | Trial primary completion date: Mar 2030 --> Jun 2029
- | Venclexta (venetoclax) / Roche, AbbVie
Phase classification, Combination therapy, IO biomarker: NCI-2018-01119: Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 30, 2023
P1/2, N=116, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Mar 2030 --> Jun 2029 | Trial primary completion date: Mar 2030 --> Jun 2029 Phase classification: P1b/2 --> P1/2
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Enrollment closed: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 28, 2023
P2, N=88, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Phase classification: P1b/2 --> P1/2 Recruiting --> Active, not recruiting
- || Starasid (cytarabine ocfosfate) / Nippon Kayaku
Biomarker, PK/PD data, Journal: Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs. (Pubmed Central) - Nov 21, 2023
Oral CO may produce prolonged serum Ara-C half-lives at concentrations sufficient to induce functional changes in peripheral leukocytes and is associated with prolonged retention of DNA-incorporated Ara-CTP. Application of functional and active metabolite assessment is feasible and may provide more relevant data to determine optimal dosing regimens for Ara-C-based treatments.
- | Venclexta (venetoclax) / Roche, AbbVie, DS-1594 / Daiichi Sankyo
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 12, 2023
P1/2, N=17, Completed, Sponsor: M.D. Anderson Cancer Center
Application of functional and active metabolite assessment is feasible and may provide more relevant data to determine optimal dosing regimens for Ara-C-based treatments. Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Nov 2023 | Trial primary completion date: Nov 2024 --> Nov 2023
- || pivekimab sunirine (IMGN632) / Jazz
Trial initiation date: Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms (clinicaltrials.gov) - Nov 8, 2023
P1, N=30, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Center
Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Nov 2023 | Trial primary completion date: Nov 2024 --> Nov 2023 Initiation date: Nov 2023 --> Feb 2024
- | Vanflyta (quizartinib) / Daiichi Sankyo
Trial completion date, Trial primary completion date: Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Nov 7, 2023
P1/2, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Nov 2023 --> Feb 2024 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Trial completion date, Trial primary completion date: Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 7, 2023
P1/2, N=50, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025 Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 2, 2023
P3, N=6720, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026 Suspended --> Recruiting
- | Opdivo (nivolumab) / Ono Pharma, BMS, Rydapt (midostaurin) / Novartis
Enrollment change, Trial completion date: Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Nov 1, 2023
P2/3, N=78, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting N=1670 --> 78 | Trial completion date: Aug 2023 --> Oct 2024
- | Vanflyta (quizartinib) / Daiichi Sankyo
Trial completion date, Trial primary completion date: Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Oct 30, 2023
P1/2, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=1670 --> 78 | Trial completion date: Aug 2023 --> Oct 2024 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed, Enrollment change: NCI-2018-01186: Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 30, 2023
P2, N=21, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Recruiting --> Active, not recruiting | N=60 --> 21
- | bortezomib / Generic mfg., thioguanine / Generic mfg.
Trial completion date: AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 24, 2023
P3, N=847, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=60 --> 21 Trial completion date: Sep 2023 --> Sep 2024
- | pevonedistat (MLN4924) / Takeda
Trial completion date, Combination therapy: ADVL1712: Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Oct 24, 2023
P1, N=12, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2023 --> Sep 2024 Trial completion date: Oct 2023 --> Sep 2024
- | revumenib (SNDX-5613) / Syndax Pharma
Trial initiation date, Combination therapy: Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene (clinicaltrials.gov) - Oct 23, 2023
P1b, N=28, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Oct 2023 --> Sep 2024 Initiation date: Jun 2023 --> Oct 2023
- | thioguanine / Generic mfg.
Trial completion date: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Oct 18, 2023
P2, N=78, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jun 2023 --> Oct 2023 Trial completion date: Jun 2024 --> Sep 2024